A metabolic-radioimmune signature predicts therapy response and immune reprogramming in non-small cell lung cancer
Radiotherapy-induced metabolic reprogramming in TIME drives resistance of NSCLC. The RRMG signature predicts radioimmunotherapy outcomes for patient stratification. Identifying ouabain and novel compounds highlights targeting metabolic vulnerabilities as a translatable strategy to overcome resistance.
Authors
- Meng‐Lin Jiang
- Guanglu Dong (ORCID: https://orcid.org/0000-0002-5737-3946)
- Zihong Zhu
- Dawei Chen (ORCID: https://orcid.org/0000-0002-6762-7997)
- Ran Zhang (ORCID: https://orcid.org/0000-0003-3376-6945)
- Yichen Zan
Institutions
- Weifang Medical University (CN)
- Harbin Medical University (CN)
- Second Affiliated Hospital of Harbin Medical University (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-11-11
- DOI
- https://doi.org/10.3389/fonc.2025.1693277
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00